Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy.
The impact of different antimicrobial regimens for intra-abdominal infections on the frequency of bowel colonization with vancomycin-resistant enterococci (VRE) was examined in 2 randomized open-label trials of intra-abdominal infection comparing piperacillin-tazobactam or ceftriaxone/metronidazole with ertapenem. In these short-term studies, overall rates of bowel colonization with VRE were generally comparable after treatment with piperacillin-tazobactam, ceftriaxone/metronidazole, or ertapenem.
DiNubile
Mark J
MJ
Merck & Co., Inc., Whitehouse Station, NJ, USA. mark_dinubile@merck.com
Friedland
Ian R
IR
Chan
Christina Y
CY
Motyl
Mary R
MR
Giezek
Hilde
H
McCarroll
Kathleen
K
Shivaprakash
Malathi
M
Quinn
John P
JP
Weinstein
Robert A
RA
Chow
Joseph W
JW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016983:Enterococcus / Q000187:drug effects* / Q000254:growth & development* / Q000302:isolation & purification; D000077727:Ertapenem; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006801:Humans; D007422:Intestines / Q000382:microbiology*; D008297:Male; D008875:Middle Aged; D020713:Vancomycin Resistance; D047090:beta-Lactams / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D000077727:Ertapenem